Nosinotropic, generically known as sacubitril valsartan sodium tablets, is a new type of medication for the treatment of heart failure, which is effective in treating adult patients with chronic heart failure with reduced ejection fraction (NYHA class II-IV). Sacubitril valsartan sodium tablets, which is originally an antihypertensive drug, can also be used in patients with chronic heart failure (NYHA class II-IV) with reduced ejection fraction, with the therapeutic goal of reducing mortality in cardiovascular patients, and also reducing the risk of hospitalization due to an acute episode in patients with heart failure. Sacubitril valsartan sodium tablets contain mainly enkephalinase inhibitors, which can lower blood pressure and control heart failure by blocking angiotensin ll receptors via valsartan. Those who are allergic to any of the components of this product need to be contraindicated, and should be used with caution if there is severe hypovolemia. Nausea, vomiting, as well as other adverse reactions during the use of the drug need to be promptly discontinued. Before using Sacubitril Valsartan, you need to consult your doctor and be under his supervision.